SCHEMBL8701967

SCHEMBL8701967

CCCCOC(=O)ON1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 3/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 3/20 0.42
ATM Q13315 1/20 0.41
MEN1 O00255 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8683226 0.98 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MAPTKMT2ANPC1
SCHEMBL8681182 0.93 L3MBTL1 (0.48) MAPTKMT2AL3MBTL1MAPK1NPSR1
SCHEMBL8682202 0.93 L3MBTL1 (0.48) MAPTKMT2AL3MBTL1MAPK1NPSR1
SCHEMBL8682101 0.93 L3MBTL1 (0.48) MAPTKMT2AL3MBTL1MAPK1NPSR1
SCHEMBL8682196 0.93 L3MBTL1 (0.48) MAPTKMT2AL3MBTL1MAPK1NPSR1
SCHEMBL8683103 0.93 L3MBTL1 (0.48) MAPTKMT2AL3MBTL1MAPK1NPSR1
SCHEMBL8681141 0.93 L3MBTL1 (0.47) ALDH1A1SMN1; SMN2MAPTKMT2ANPC1
SCHEMBL8681074 0.91 NAAA (0.47) ALDH1A1MAPTKMT2AL3MBTL1MAPK1
SCHEMBL8681006 0.91 NAAA (0.47) ALDH1A1MAPTKMT2AL3MBTL1MAPK1
SCHEMBL8682077 0.91 NAAA (0.47) ALDH1A1MAPTKMT2AL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed